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The identification of selective benzodiazepine site ligands, endowed with anxiolytic and anti-hyperalgesic
action, is a relevant opportunity for the treatment of pain syndromes. Previously, we selected a compound
with a promising anti-hyperalgesic profile, the 3-iodo-8-benzylaminopyrazolo [5,1-c][1,2,4]benzotriazine
5-oxide. Aimed to verify the structure–activity relationship, the corresponding 7-arylakylamino derivatives
were synthesized. Compounds were tested for their affinity at GABAA-receptor subtype; the compound
12 was further investigated in animal models of anxiety and persistent pain.
J. Heterocyclic Chem., 00, 00 (2017).
INTRODUCTION
Chronic pain, a complex disorder associated with various
pathological processes, is defined as pain that persists
longer than the temporal course of natural healing; it has a
profound impact on many aspects of daily life with
quality-of-life connection and socioeconomic
implications. In fact, a higher frequency of mood and
anxiety disorders and the occurrence of suicidal ideation
are not inconsequential in this pathological process. It is
categorized as inflammatory or neuropathic pain and
treated with opioids and non-steroidal anti-inflammatory
drugs both inadequate for long-term therapy because of
the well-known adverse events. The need to better
understand chronic pain mechanisms and to create novel
and effective multimodal treatment options strongly
encourages the research in this field.
Among the neurotransmitters involved in pain signaling,
the γ-aminobutyric acid (GABA) plays an important role.
The block of the spinal GABAergic neurotransmission by
intrathecal injection of GABA receptor antagonist
produces hyper-sensitivity to innocuous stimuli, while
compounds activating the GABAA receptors
(GABAA-Rs), such as agonists or positive allosteric
modulators, have been proposed as potent analgesics in
various models of inflammatory and neuropathic pain [1].
Briefly, GABAA-Rs belong to the family of
heteropentameric ion channel and present a typical
composition containing 2α, 2β, 1γ subunits; inside the
pentamer, the benzodiazepines site (Bdz site, also known
as GABAA-R subtype) lies between the α/γ subunits and
the pharmacological effect of ligands depends on the type
of α-subunit present (α1–6) [2,3]. It is well known that
the α1 subunit is involved in an anticonvulsant and
sedative effect, the α2/α3 subunits are involved in an
anxiolytic-like effect, and the α5 subunit in memory [4].
After preliminary studies [5] indicating the relationships
among analgesia, GABAA receptors, and benzodiazepine
ligands, Knabl [6] and Ralvenius [7] presented innovative
pharmacological data using several lines of mice with
genetically modified GABAA receptors (GABAA-Rs
point-mutated mice) and demonstrated that the spinal
anti-hyperalgesic effect was mediated by the α2- or α3-
GABAAR subtypes. Among the examples reported in
Figure 1, compound L-838,417, a α2/α3-selective
GABAA-R subtype ligand, exerts pronounced anti-
hyperalgesic action without producing sedation, motor
impairment, or tolerance development [8]. Other partial
allosteric modulators of α2-, α3-, and/or α5-containing
GABAA-Rs, NS11934, SL-651498, and TPA023 showed
analgesic properties in models of inflammatory and
neuropathic pain [5,9–11]. Moreover, recent literature
reports HZ166 [12], with selective efficacy at α2 and α3
subunit-containing GABAA-Rs, endowed with anti-
hyperalgesic effect (Fig. 1). Such compounds might be
useful for the treatment of chronic pain syndromes
that have become unresponsive to classical analgesic
drugs [13].
© 2017 Wiley Periodicals, Inc.
Our research group has been extensively involved in the
design and synthesis of pyrazolo[5,1-c][1,2,4]
benzotriazine (PBT) derivatives, with the aim to identify
selective GABAA-R subtype (Bdz site) ligands. Our
previous studies let us to individuate the 3-iodo-8-
benzylamino PBT (lead A) [14] reported in Figure 1, a
promising compound with Ki = 0.109 ± 0.008 nM and
provided with selective anxiolytic and anti-hyperalgesic
effect, thus acting as a α2-subtype agonist. Its pain
relieving efficacy was preclinically shown against trauma-
induced peripheral nerve pain neuropathy and diabetic
neuropathy, taking effect at 3 mg kg1 per os.
Because the importance of the 8-NH group for the
anxiolytic and anti-hyperalgesic effect was highlighted in
the series of 3,8-disubstituted PBT [14], we aimed to
verify if the shift of the NH from 8- to 7-position still
allows the pharmacological activity. Thus, we synthesized
7-arylalkylaminopyrazolo [5,1-c][1,2,4benzotriazines
3-substituted (I, CH3, triazole) to optimize lead A [14].
Moreover, some 8-arylalkylaminoderivatives were
synthesized ad hoc to better compare the two series. All
synthesized compounds were tested for their affinity at
GABAA-R subtype, and in vivo pharmacological tests
were performed.
RESULTS AND DISCUSSION
Chemistry. All compounds described here are listed in
Table 1. A first attempt to obtain the 3-iodo-7-
arylalkylaminopyrazolo[5,1-c][1,2,4]benzotriazine derivatives
was made starting from compound 1, the 7-
aminopyrazolo[5,1-c][1,2,4]benzotriazine [15] that was
undergone to reductive N-alkylation by using the suitable
aromatic aldehyde and sodium cianoborohydride in the
presence of Lewis acid as ZnCl2 [16]. The first term of
this series, the 7-benzylamino derivative 3, was easily
obtained through the intermediate Schiff base (2) that was
isolated and reduced. Unfortunately, the following
iodination gave a mixture of 3,6- and 3,8-diiodio-7-
benzylaminopyrazolo[5,1-c][1,2,4]benzotriazines, not easily
separable (compounds a and b), Scheme 1. Thus, because
the final iodination represented the critical step to obtain the
desired compounds, we followed a different synthetic
strategy using the 3-iodio-7-aminopyrazolo[5,1-c][1,2,4]
pyrazolobenzotriazine, 6a, as key intermediates (Scheme 2).
This compound was indifferently obtained either by acid
hydrolysis of 5 or by reduction with SnCl2 [17] of 8
synthesized from the corresponding 3-unsubstituted
compounds 4 and 7, respectively [15,18], by treatment with
iodine monochloride. Instead, to obtain the 3-methyl-7-
aminopyrazolo[5,1-c][1,2,4] pyrazolobenzotriazine, 6b, the
reduction of 9 (3-carboxylic derivative) with borane
dimethyl sulfide complex (Me2SBH3) was performed
(Scheme 2).
The key intermediate 6a then treated with
benzoylchloride to give the corresponding N-(3-
iodopyrazolo[5,1-c][1,2,4]benzotriazin-7-yl)benzamide 10;
the reductive N-alkylation of 6a with suitable (hetero)
arylaldehyde and sodium cianoborohydride/ZnCl2 afforded
the corresponding 3-iodio-7-arylalkylaminoderivatives
11a–d. Compound 11a was, in turn, oxidized with
m-chloroperbenzoic acid to the related N5-oxide, 12
(Scheme 3). Compound 6b was transformed into the final
products 13a–c (Scheme 4) following the same method
of reductive N-alkylation.
To achieve compounds 3-(1,2,4-triazol-5-yl)pyrazolo-
[5,1-c][1,2,4]benzotriazine 7- and 8-N-arylalkyl substituted
18a–d and 21b–d, the first step was the building of the
triazole ring at 3-position starting from the amide
function. Following a procedure already described [19],
the starting material, 3-carbamoyl- derivative 14 [18],
was treated with dimethylformamide-dimethylacetal (DMF-
DMA)/toluene to give the 3-(N-(dimethylaminomethylene)
carbamoyl derivative 15, and then with hydrazine hydrate
to afford the 3-(1,2,4-triazol-5-yl) derivative 16. The nitro
group at position 7 of this latter was reduced with
Sn/HCl to obtain the 7-amine, N5-deoxide compound 17,
which was, finally, treated as usual with the suitable
aromatic aldehyde and sodium cianoborohydride to give
compounds 18a–d (Scheme 5).
The synthetic procedure followed to obtain PBTs
bearing the arylalkylamino chain at position 8 is depicted
in Scheme 6.
Figure 1. Chemical structures of reference compounds.
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The 3-carbamoyl-8-chloropyrazolo[5,1-c][1,2,4]benzotr
iazine 5-oxide 19 [18] was transformed into the 3-triazol-
derivative 20 [19], which was then converted into the 8-
N-arylalkylamino derivatives through the aromatic
nucleophilic substitution of chlorine, in the presence of
an excess of suitable aryl amine (final 5-N-oxide products
21b–d). To obtain 21a is more advantageous as yields
pureness first to synthesize the 8-benzylamino derivative
22, by the nucleophilic substitution of chlorine on the
PBT 19 [18] with benzylamina, and then to perform the
usual reaction with DMF-DMA (23), followed by the
treatment with hydrazine hydrate (Scheme 6).
Biological results. In vitro binding. The Bz
site/GABAA-R binding affinity of newly synthesized
compounds was evaluated for their ability to displace
[3H]flumazenil (Ro15–1788) from its specific binding in
a bovine brain membrane.
Final products (10–13, 18a–d, 21a–d) were tested at
fixed concentrations of 10 μM, and the Ki value was
expressed only for those terms inhibiting radioligand
binding by more than 80%. Looking at Table 2, it emerges
that, for the most part of the new products, this value is
less than 60% with only few exceptions. In the series of 3-
iodo PBT, only the 7-benzylamino derivatives 11a and 12
Table 1
Chemical data for PBT derivatives.
R3 R7 R8 X Formula (MW)
mp°C
(recryst. solvent)
1a H NH2 —
2 H N═CHPh — C16H11N5 (273.29) 280–281°C
3 H NHCH2Ph — C16H13N5 (275.30) 292–293°C
4a H NHCOCH3 —
5 I NHCOCH3 — C11H8N5OI (353.11) 248–249°C
6a I NH2 — C9H6N5I (311.14) 208–210°C
6b CH3 NH2 — C10H9N5 (199.18) 298–299°C
7b H NO2 O
8 I NO2 O C9H4N5O3I (357.14) 270–272°C
9b COOH NO2 O
10 I NHCOPh — C16H10N5OI (414.99) >300°C
11a I NHCH2Ph — C16H12N5I (401.4) >300°C
11b I NHCH2-4-Cl-Ph — C16H11N5ICl (435.53) >300°C
11c I NHCH2-2-Py — C15H11N6I (402.01) >300°C
11d I NHCH2-2-furyl — C11H10N5OI (391.16) >300°C
12 I NHCH2Ph O C16H12N5OI (417.4) >300°C
13a CH3 NHCH2Ph — C17H15N5 (289.31) 273–274°C
13b CH3 NHCH2-4-Cl-Ph — C17H14N5Cl (323.75) 279–280°C
13c CH3 NHCH2-2-Py — C16H14N6 (290.28) 299–300°C
14b CONH2 NO2 O
15 CON═CHN(CH3)2 NO2 O C13H11N7O4 (329.27) >300°C
16 1,2,4-triazol-5-yl NO2 O C11H6N8O3 (298.22) >300°C
17 1,2,4-triazol-5-yl NH2 — C11H8N8 (252.22) >300°C
18a 1,2,4-triazol-5-yl NHCH2Ph — C18H14N8 (342.28) >300°C
18b 1,2,4-triazol-5-yl NHCH2-4-Cl-Ph — C18H13N8Cl (376.81) >300°C
18c 1,2,4-triazol-5-yl NHCH2-2-Py — C17H13N9 (343.35) >300°C
18d 1,2,4-triazol-5-yl NHCH2-2-furyl — C16H12N8O (332.33) >300°C
19b CONH2 Cl O
20c 1,2,4-triazol-5-yl Cl O
21a 1,2,4-triazol-5-yl NHCH2Ph O C18H14N8O (358.28) >300°C
21b 1,2,4-triazol-5-yl NHCH2-4-Cl-Ph O C18H13N8OCl (392.81) >300°C
21c 1,2,4-triazol-5-yl NHCH2-2-Py O C17H13N9O (359.35) >300°C
21d 1,2,4-triazol-5-yl NHCH2-2-furyl O C16H11N8O2 (348.33) >300°C
22 CONH2 NHCH2Ph O C17H14N6O2 (334.12) 280°C dec.
23 CON═CHN(CH3)2 NHCH2Ph O C20H19N7O2 (389.42) >300°C
a[15]
b[18]
c[19]
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show an appreciable affinity: Ki = 0.914 ± 0.10 μM and
Ki = 0.28 ± 0.029 μM, respectively.
Also in the 3-methyl- and 3-(triazol-5-yl)- series (13a–c
and 18a–d), the only compounds endowed with a certain
affinity are 13a and 18a, both showing the benzylamino
fragment at position 7.
Finally, the biological data of compounds 21a–d (the
isomers of 18a–d), in which the (hetero)arylamino
moiety was shifted from 7 to 8-position, further confirm
the importance of the benzylamino fragment for binding
affinity (21a, Ki = 1.44 ± 0.11 μM).
In vivo activity. Compound 12 was selected for its best
affinity, and we decided to investigate the pharmacological
profile by evaluating the anxiolytic-like, anticonvulsant,
and anti-hyperalgesic activity. Derivative 12 is the
7-isomer of our lead compound A, (3-iodo-8-
benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
Fig. 1), characterized by a selective anxiolytic profile
joined to anti-hyperalgesic effects in animal pain models,
starting from the dose of 3 mg kg1 per os [14].
Accordingly to the notion that the benzodiazepines are
generally not analgesic per se, the GABAA-subtype
Scheme 1. Reagents and conditions: (i) PhCHO/MeOH/AcOH; (ii)
MeOH/NaBH4; (iii) ICl/CH2Cl2.
aSee [15].
Scheme 2. Reagents and conditions: (i) ICl/CH2Cl2; (ii) HCl, NaOH; (iii)
SnCl2/EtOH; (iv) THF/(CH3)2SBH3.
aSee [15]. bSee [18].
Scheme 3. Reagents and conditions: (i) NaOH, benzoylchloride;
(ii) Ar/HetCHO (a-d, benzaldehyde a, 4-chlorobenzaldheyde b, 2-
pyridincarboxyaldheyde c and 2-furylcarboxyaldheide d), NaCNBH3/ZnCl2/
MeOH; (iii) MCPBA/CH2Cl2.
Scheme 4. Reagent and conditions: (i) Ar/HetCHO (a‐c, benzaldehyde a,
4‐chlorobenzaldheyde b, 2‐pyridincarboxyaldheyde c), NaCNBH3/ZnCl2/
MeOH.
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ligands can exert anti-hyperalgesic action overall when the
pain sensitivity is pathologically increased (inflammation
or neuropathic injury) [9,20].
The effects on mouse anxiety were studied using a
light/dark box apparatus. Compound 12 was tested in the
dose range 10–30 mg kg1 p.o. showing good anxiolytic-
like effect with an efficacy comparable to diazepam
(standard reference). The anxiolytic-like effects were
completely antagonized by flumazenil (100 mg kg1
intraperitoneally), suggesting that the anxiolytic-like
effect is exerted through the GABAA-R subtypes (Bdz
site), Table 3.
Moreover, the pain relieving profile of compound 12
(3–10-30 mg kg1 p.o.) was evaluated in animals that
underwent the chronic constriction injury of the sciatic
nerve (according to the method described by Bennett and
Xie [21]). Behavioral measurements were performed on
day 14 after the surgery when hyperalgesia was
established. The nociceptive threshold was determined by
the paw pressure test measuring the sensitivity to a
mechanical noxious stimulus [22]. The pain threshold of
the ipsilateral paw was significantly reduced in
comparison to the contralateral, uninjured, paw (Table 4).
As shown in Table 4, 30 mg kg1, compound 12 p.o.
induced a statistically significant anti-hyperalgesic
activity in comparison with the vehicle-treated group
(Table 4).
Compound 12 was also tested in the animal model of
streptozotocin (STZ)-induced hyperalgesia, which
reproduces pain related to diabetic neuropathy in
laboratory animals. STZ is toxic for the insulin-producing
beta cells of the pancreas in mammals, and it drastically
increases the serum glucose level. In diabetic patients,
hyperglycemia-induced oxidative stress has been
considered the main cause of diabetic neuropathy [23].
STZ-induced hyperalgesia was measured by the hot plate
test (Table 5); 12 (30 mg kg1 p.o.) significantly
increased the pain threshold 15, 30, 45, and 60 min after
the administration (Table 5).
On the other hand, compound 12 (10–30 mg kg1 p.o.)
did not show antinociceptive activity in the Writhing test, a
model of irritative pain induced by the injection i.p. of
acetic acid. Finally, the protection from convulsions was
evaluated in mice using pentylentetrazole (PTZ) as a
chemical convulsant agent. Compound 12 (10–30 mg kg1
p.o.) was devoid of any effect on PTZ-shock with respect
to the reference drug (diazepam, 1 mg kg1 i.p.).
Because it was reported that the anticonvulsant effects
are principally because of the activation of the α1
GABAA-R subtype [24,25], the lack of this effect could
be related to the antagonist efficacy of 12 at this receptor
subtype. This result suggests that the mechanism of action
responsible for the anti-hyperalgesic effect of 12 is not
associated with anticonvulsant activity [26–29].
Scheme 5. Reagent and conditions: (i) DMF-DMA/Toluene; (ii) N2H4.
H2O/AcOH; (iii) Sn/HCl; (iv) Ar/HetCHO (a-d, benzaldehyde a, 4-
chlorobenzaldheyde b, 2-pyridincarboxyaldheyde c and 2-furylcarboxyaldheyde
d), NaCNBH3/ZnCl2/MeOH.
aSee [18].
Scheme 6. Reagents and conditions: (i) PhCH2NH2 for 22 and Ar/
HetCH2NH2 for 21b–d; (ii) DMF-DMA/Toluene; (iii) N2H4.H2O/
AcOH. aSee [19]. bSee [18].
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Table 2
BZR ligand affinity of new synthesized compounds.
R3 R7 R8 X I% or Ki (μM)
a
10 I NHCOPh — 5%
11a I NHCH2Ph — 0.914 ± 0.10
11b I NHCH2-4-Cl-Ph — 25%
11c I NHCH2-2-Py — 57%
11d I NHCH2-2-furyl — 35%
12 I NHCH2Ph O 0.28 ± 0.02
13a CH3 NHCH2Ph — 5.08 ± 0.3
13b CH3 NHCH2-4-Cl-Ph — 34.5%
13c CH3 NHCH2-2-Py — 1%
18a 1,2,4-triazol-5-yl NHCH2Ph — 1.88 ± 0.23
18b 1,2,4-triazol-5-yl NHCH2-4-Cl-Ph — 15.3%
18c 1,2,4-triazol-5-yl NHCH2-2-Py — 48%
18d 1,2,4-triazol-5-yl NHCH2-2-furyl — 28%
21a 1,2,4-triazol-5-yl NHCH2Ph O 1.44 ± 0.11
21b 1,2,4-triazol-5-yl NHCH2-4-Cl-Ph O 9%
21c 1,2,4-triazol-5-yl NHCH2-2-Py O 33.4%
21d 1,2,4-triazol-5-yl NHCH2-2-furyl O 43%
Lead A I NHCH2Ph O 0.109 ± 0.008 nM
aPercent of inhibition of specific [3H]Ro 15-1788 binding at 10 μM concentration or Ki, are means ± SEM of five determinations.
Table 3
Anxiolytic-like effect of 12 in light–dark box test.
Treatment mg/kg Persistent time in light box (min)
CMC 1% 119.3 ± 9.1
flumazenil 100 mg kg1 (i.p.) 120.6 ± 7.3
diazepam 1 10 mg kg1 165.6 ± 9.1*
12 10 mg kg1 129.4 ± 7.7
12 30 mg kg1 153.6 ± 7.2*
12 + flumazenil 30 mg kg1 + 100 mg kg1 129.3 ± 8.9**
Compound (p.o.) and diazepam were administered 30 min and flumazenil (flu, i.p.) before the test. Each value represents at least eight mice.
*P < 0.01 versus saline-treated mice.
**P < 0.01 versus the flumazenil-treated mice.
Table 4
Anti-hyperalgesic effect of 12 (CCI, paw-pressure test).
Treatment mg kg1 p.o Paw
Paw pressure in rats (g)
Before treatment After treatment
15 min 30 min 45 min
CMC contra 60.3 ± 3.5 63.5 ± 3.1 62.9 ± 3.1 59.6 ± 2.6
CMC ipsi 28.5 ± 3.1 25.7 ± 3.8 24.2 ± 3.9 28.2 ± 3.3
12 3 contra 58.7 ± 3.2 63.3 ± 3.2 59.4 ± 2.8 64.5 ± 3.6
3 ipsi 25.3 ± 3.3 32.7 ± 3.1 35.7 ± 3.5 33.9 ± 2.4
10 contra 62.6 ± 3.0 58.4 ± 3.6 64.2 ± 3.4 60.8 ± 2.5
10 ipsi 27.8 ± 2.9 34.5 ± 3.8 34.8 ± 4.1 30.3 ± 3.4
30 contra 58.5 ± 3.2 66.4 ± 4.0 57.3 ± 3.9 61.9 ± 3.5
30 ipsi 28.9 ± 3.7 47.9 ± 3.9* 46.2 ± 2.8* 38.0 ± 3.2
The paw pressure test was performed on the ipsilater paw (ipsi) in comparison to the contralateral (contra) unaltered paw. There were at least six rats per
group.
*P < 0.01.
G. Guerrini, G. Ciciani, L. Crocetti, S. Daniele, C. Ghelardini, M. P. Giovannoni,
L. Di Cesare Mannelli, C. Martini, and C. Vergelli
Vol 000
Journal of Heterocyclic Chemistry DOI 10.1002/jhet
On the basis of binding results, it emerges that only
derivatives bearing the 7-benzylamino group (11a, 12,
and 13a) show receptor recognition (Ki range 0.28–
5.08 μM). Thus it is possible to hypothesize that, despite
the simultaneous presence of a lipophilic group at
position 3 (I and CH3) and of a group that engages a
hydrogen bond at 7-position (NH), [14] a different fit into
receptor protein with respect the 8-isomers occurs (data
not published). The same trend is verified also in the
3-triazole derivatives (18a and 21a). All these molecules
will be inserted in a next study of molecular dynamic to
evaluate the occurrence of hydrogen bonds and Van der
Walls interactions, between the ligand and the amino
acids of receptor protein [30].
CONCLUSION
All new compounds 7-arylalkylamino derivatives, designed
as isomers of the active 8-arylalkylaminopyrazolo[5,1-c]
[1,2,4]benzotriazines, surprisingly have very low affinity at
GABAA-R subtype. Within this series, only the
7-benzylamino derivatives 11a, 12, 13a, and 18a have
affinity in micromolar range, showing that the phenyl of the
benzylamino chain must be unsubstituted and it cannot be
replaced with a heteroaryl ring. The most affine compound
was 12, and because it is the 7-isomer of the lead A,
pharmacological in vivo activity was assessed. Compound
12 showed anxiolytic-like effect and anti-hyperalgesic profile
in mono-neuropathic pain and in diabetic neuropathy at
10–30 mg kg1, while it was not able to revert the
inflammatory pain. Thus, the shift of the NH moiety from
8- to 7-position (from lead A to compound 12) was
detrimental for the binding affinity, probably because the
NH hydrogen bond donor is not in the suitable position to
engage strong interaction with the receptor protein [14,31]
responsible for a good affinity value. On the other hand,
the retention of anxiolytic-like and anti-hyperalgesic activity
seems to indicate that the evoked efficacy (intrinsic
activity) by compound 12 is however that of a α2-agonist,
analogously to the 8-arylalkylamino isomers, confirming
that between affinity and efficacy, the efficacy parameter is
more important.
EXPERIMENTAL
Chemistry. General. Melting points were determined
with a Gallenkamp apparatus and were uncorrected. Silica gel
plates (Merk F254) and silica gel 60 (Merk 70–230 mesh) were
used for analytical and column chromatography, respectively.
The structures of all compounds were supported by their IR
spectra (KBr pellets in nujol mulls, Perkin-Elmer 1420
spectrophotometer) that showed characteristic absorption band
corresponding to N─H stretching, and 1H-NMR data (measured
with a Bruker 400 MHz). Chemical shifts were expressed in δ
ppm, using DMSO-d6 or CDCl3 as solvent. The chemical and
physical data of new compounds are shown in Table 1;
microanalyses were performed with a Perkin-Elmer 260
analyzer for C, H, N; the molecular formula and formula weight
are reported in Table 1.
7-Benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine (3). A
solution of 7-aminopyrazolo[5,1-c][1,2,4]benzotriazine (1) [15]
(0.25 mmol) in methanol (10 mL) and five drops of acetic acid
was maintained under anhydrous N2 for 1 h. Benzaldehyde
(1:1, 0.026 mL) was added, and the reaction was maintained
under reflux until the starting material disappeared (TLC). The
solvent was evaporated to dryness, and the formation of the
intermediate Base of Schiff 2 was evaluated by 1H-NMR on
raw material. TLC eluent: dichloromethane/ethyl acetate
7:3 v/v; 1H-NMR (DMSO-d6) δ 8.92 (s, 1H, CH); 8.53 (m,
2H, H-6 and H-9); 8.47 (d, 1H, H-2); 8.10 (dd, 1H, H-8); 8.07
(dd, 2H, H-20, and H-60); 7.65 (d, 1H, H-3); 7.61 (m, 3H,
H-30, H-40, and H-50). Anal. Calcd C, H, N: C, 70.32%; H,
4.06%; N, 25.63%. Found: C, 70.25%; H, 4.08%; N, 25.59%.
The second step of the reaction was the reduction of Base of
Schiff 2, by the addition of sodium borohydride (0.5 mmol) in
methanol at reflux temperature for 2 h. At the end of the
reaction (monitored by TLC), a solution of 10% sodium
hydroxide was added and the precipitate, compound 3, was
filtered and recrystallized by suitable ethanol. TLC eluent:
dichloromethane/ethyl acetate 7:3 v/v; IR ν cm1 3331.
1H-NMR (CDCl3) δ 8.27 (d, 1H, H2); 8.24 (d, 1H, H-9); 7.58
(dd, 1H, H-8); 7.46 (d, 2H, H-20, and H-60); 7.43 (m, 2H, H-3,
and H-6); 7.38 (t, 2H, H-30, H-40); 7.28 (t, 1H, H-40); 7.20 (t,
1H, NH exch.); 4.48 (d, 1H, CH2). Anal. Calcd C, H, N: C,
69.80%; H, 4.76%; N, 25.44%. Found: C, 69.82%; H, 4.73%;
N, 25.49%.
Table 5
Anti-hyperalgesic effect of 12 (SZT, mouse hot-plate test).
Pre-treatment
Licking latency in mice (s)
Treatment i.p. mg kg1 Before treatment after treatment
15 min 30 min 45 min 60 min
CMC CMC 16.9 ± 0.9 18.4 ± 1.3 19.2 ± 1.2 18.5 ± 1.3 18.1 ± 1.4
STZ CMC 9.6 ± 0.5 10.1 ± 1.2 10.2 ± 0.7 9.9 ± 1.1 9.2 ± 0.9
CMC 12 30 15.1 ± 1.1 17.0 ± 1.2 17.8 ± 1.0 15.3 ± 1.5 15.6 ± 1.2
STZ 12 30 9.3 ± 0.9 15.4 ± 1.0* 15.9 ± 0.7* 16.7 ± 1.0* 15.5 ± 1.3*
Streptozotocine (STZ) 200 mg kg1 i.p. was dissolved in citrate buffer and injected 21 days before experiment. Each value represents the mean of at least
10 mice.
*P < 0.01 in comparison with STZ-treated mice.
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General procedure for the synthesis of 5 and 8. The
starting materials, 7-acetamidopyrazolo[5,1-c][1,2,4]benzotriazine,
4 and 7-nitropyrazolo[5,1-c][1,2,4]pyrazolobenzotriazine 5-oxide,
7 [[15],[18]] (0.2 mmol), respectively, were dissolved in
dichloromethane (5 mL), and a solution of iodine monochloride
in dichloromenthane (0.4 mmol/2 mL) was added and
maintained at room temperature. The reaction was monitored by
TLC; after 5 h, the solution was evaporated to dryness and the
residue was recovered by treatment with water, made slightly
alkaline with a 5% sodium hydroxide solution.
3-Iodo-7-acetamidopyrazolo[5,1-c][1,2,4]benzotriazine (5).
From 4 [15]; yellow crystals; yield 70% from ethanol; TLC eluent:
toluene/ethyl acetate/methanol 8:2:1 v/v/v; IR ν cm1 3214, 1680;
1H-NMR (DMSO-d6) δ 10.56 (s, 1H, NH exch.); 9.01 (d, 1H, H-
6); 8.52 (s, 1H, H-2); 8.42 (d, 1H, H-9); 8.15 (dd, 1H, H-8); 2.12
(s, 3H, CH3). Anal. Calcd C, H, N: C, 37.41%; H, 2.28%; N,
19.83%. Found: C, 37.53%; H, 2.25%; N, 19.88%.
3-Iodo-7-nitropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
(8). From 7 [18]; yellow crystals; yield 85% from ethanol;
TLC eluent: toluene/ethyl acetate/methanol 8:2:1 v/v/v; IR ν
cm1 1570, 1540, 1350; 1H-NMR (DMSO-d6) δ 9.02 (d, 1H,
H-6); 8.80 (dd, 1H, H-8); 8.52 (s, 1H, H-2); 8.49 (d, 1H, H-9).
Anal. Calcd C, H, N: C, 30.27%; H, 1.13%; N, 19.61%. Found:
C, 30.41%; H, 1.15%; N, 19.68%.
3-Iodo-7-aminopyrazolo[5,1-c][1,2,4]benzotriazine (6a). This
product was obtained from 5 or 8 in two different methods.
A suspension of 5 (0.2 mmol) in 15 mL of 6N hydrochloride
acid was maintained at reflux temperature for 5 h. After cooling,
the residue was treated with 10% sodium hydroxide solution
and the precipitate was filtered and recrystallized. Yield 80%.
A solution of 8 (0.2 mmol) in methanol (5 mL) was added of
SnCl2 [17] in a ratio of 1:5. The reaction was maintained at
reflux temperature for 10 h until the starting material
disappeared; the final solution was made alkaline with
water/sodium hydrogen carbonate and extracted with ethyl
acetate. The evaporation of the organic layer gave a residue
recrystallized with ethanol 80%. Yield 85%. Red crystals; TLC
eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v; IR ν cm1
3460, 3360; 1H-NMR (DMSO-d6) δ 8.37 (s, 1H, H-2); 8.18 (d,
1H, H-9); 7.58 (d, 1H, H-6); 7.45 (dd, 1H, H-8); 6.05 (bs, 2H,
NH2 exch.). Anal. Calcd C, H, N: C, 34.75%; H, 1.94%; N,
22.51%. Found: C, 34.55%; H, 1.96%; N, 22.49%.
3-Methyl-7-aminopyrazolo[5,1-c][1,2,4]benzotriazine (6b). A
suspension of 3-carboxy-7-nitropyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide 9 [18] (0.350 mmol) in THF anhydrous (10 mL) was
maintained at 0°C for 30 min, and then 0.1 mL of borane-
dimethylsulfide complex in THF was slowly added [32]. The
solution was gentle heated to reflux until the starting material
disappeared and again cooled in an ice bath, added with 10 mL of
methanol and stirred for 1 h. After, the solution was acidified with
hydrochloride acid and was again refluxed for 30 min. The
addition of 10 mL of methanol and the following evaporation of
the solvent gave a residue that was made alkaline with 10%
sodium hydroxide solution. Finally, the suspension was extracted
with ethyl ether obtaining, after evaporation, a desired crude
product that was recrystallized by water. Red crystals; yield 45%;
TLC eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v; IR ν
cm1 3460, 3360; 1H-NMR (DMSO-d6) δ 8.13 (d, 1H, H-9); 8.08
(s, 1H, H-2); 7.56 (d, 1H, H-6); 7.38 (dd, 1H, H-8); 5.91 (bs, 2H,
NH2 exch.); 2.56 (s, 3H, CH3). Anal. Calcd C, H, N: C, 60.29%;
H, 4.55%; N, 35.16%. Found: C, 60.35%; H, 4.57%; N, 35.21%.
3-Iodo-7-benzamidopyrazolo[5,1-c][1,2,4]benzotriazine (10).
A suspension of 6a (0.170 mmol) in a 10% sodium hydroxide
solution (3 mL) was added of benzoyl chloride (0.5 mL), with
attention, because the reaction is exothermic. The reaction was
maintained at room temperature for 1 h, and then the precipitate
was filtered and washed with water. Pale brown crystals; Yield
70% from ethanol; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3200; 1H-NMR (DMSO-d6) δ 10.88 (s, 1H,
NH exch.); 9.19 (d, 1H, H-6); 8.54 (s, 1H, H-2); 8.47 (m, 2H, H-9
and H-8); 8.05 (d, 2H, Ph); 7.58–7.66 (m, 3H, Ph). Anal. Calcd C,
H, N: C, 46.29%; H, 2.43%; N, 16.87%. Found: C, 46.40%; H,
2.47%; N, 16.82%.
General procedure for the synthesis of 11a–d, 13a–c, 18a–
d. A mixture of starting material 6a, 6b, and 17
(0.225 mmol) and the suitable aldehyde (benzaldehyde, 4-
chlorobenzaldehyde, 2-pyridincarboxyaldehyde, 2-furaldehyde,
a-d, 0.3 mmol) was solubilized in methanol (4 mL), and a
solution of sodium cyanoborohydride (0.8 mmol) and zinc
chloride (0.8 mmol) in methanol (2 mL) was added; the reaction
was maintained at room temperature for 8 h and monitored by
TLC. The final suspension was filtered, to eliminate the
inorganic residue, and washed with methanol. The solvent was
evaporated to dryness and alkalinized (pH 8) with a 10%
sodium hydroxide solution. The precipitate was filtered and
recrystallized by suitable solvent.
3-Iodo-7-benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine
(11a). From 6a; yield 70% from ethanol; red crystals;
TLC eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v;
IR ν cm1 3328; 1H-NMR (DMSO-d6) δ 8.27 (d, 1H, H-
6); 8.24 (d, 1H, H-9); 7.55 (dd, 1H, H-8); 7.50–7.42 (m,
6H, Ph and H-2); 7.27 (t, 1H, NH exch.); 4.50 (d, 2H,
CH2). Anal. Calcd C, H, N: C, 47.90%; H, 3.01%; N,
17.46%. Found: C, 48.28%; H, 3.03%; N, 17.42%.
3-Iodo-7-(4-chlorobenzylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine (11b). From 6a; yield 63% from ethanol;
orange crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3324; 1H-NMR (DMSO-d6) δ 8.27 (d,
1H, H-6); 8.24 (d, 1H, H-9); 7.55 (dd, 1H, H-8); 7.50 (d,
2H, Ph); 7.42 (m, 3H, Ph and H-2); 7.24 (t, 1H, NH exch.);
4.49 (d, 2H, CH2). Anal. Calcd C, H, N: C, 44.11%; H,
2.55%; N, 16.08%. Found: C, 44.28%; H, 2.54%; N, 16.06%.
3-Iodo-7-(2-pyridinylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine (11c). From 6a; yield 58% from 2-propanol;
red crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3331; 1H-NMR (DMSO-d6) δ 8.59 (d,
1H, Py); 8.37 (d, 1H, H-6); 8.23 (d, 1H, H-9); 7.78 (t, 1H,
Py); 7.59 (dd, 1H, H-8); 7.48–7.42 (m, 2H, H-2 and Py);
7.34 (t, 1H, Py); 7.30 (t, 1H, NH exch.); 4.58 (d, 2H, CH2).
Anal. Calcd C, H, N: C, 44.79%; H, 2.76%; N, 20.90%.
Found: C, 44.38%; H, 2.72%; N, 21.01%.
3-Iodo-7-(furan-2-methylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine (11d). From 6a; yield 71% from ethanol;
brown crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3328; 1H-NMR (DMSO-d6) δ 9.02 (d,
1H, H-6); 8.81(dd, 1H, H-8); 8.52 (s, 1H, H-2); 8.24 (d, 1H,
H-9); 7.60 (m, 2H, furane); 7.36 (m, 1H, furane); 6.89 (t,
1H, NH exch.); 4.50 (d, 2H, CH2). Anal. Calcd C, H, N: C,
42.99%; H, 2.58%; N, 17.90%. Found: C, 43.10%; H,
2.52%; N, 17.85%.
3-Iodo-7-benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (12). To a solution of compound 11a (0.50 mmol) in
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L. Di Cesare Mannelli, C. Martini, and C. Vergelli
Vol 000
Journal of Heterocyclic Chemistry DOI 10.1002/jhet
CH2Cl2, an excess of m-chloroperbenzoic acid was added. The
reaction was kept at 60°C and monitored by TLC. The final
precipitate was filtered and recrystallized. Yield 65% from
ethanol; red crystals; TLC eluent: toluene/ethyl acetate/acetic
acid 8:2:1 v/v/v; IR ν cm1 3315, 1580; 1H-NMR (DMSO-d6) δ
8.37 (s, 1H, H-2); 8.22 (d, 1H, H-9); 7.54 (dd, 1H, H-8); 7.48
(m, 2H, Ph); 7.42 (m, 3H, Ph and H-6); 7.30 (d, 1H, Ph); 7.27
(t, 1H, NH exch.); 4.50 (d, 2H, CH2). Anal. Calcd C, H, N: C,
46.06%; H, 2.90%; N, 16.79%. Found: C, 40.35%; H, 2.88%;
N, 16.85%.
3-Methyl-7-benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine
(13a). From 6b; yield 68% from ethanol; orange crystals; TLC
eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v; IR ν cm1
3339; 1H-NMR (DMSO-d6) δ 8.18 (d, 1H, H-9); 8.08 (s, 1H,
H-2); 7.47 (dd, 1H, H-8); 7.41 (d, 2H, Ph); 7.38 (d, 1H, H-6);
7.36 (d, 2H, Ph); 7.29 (t, 1H, Ph); 7.12 (t, 1H, NH exch.); 4.48
(d, 2H, CH2); 2.55 (s, 3H, CH3). Anal. Calcd C, H, N: C,
70.57%; H, 5.23%; N, 24.21%. Found: C, 70.43%; H, 5.26%;
N, 24.26%.
3-Methyl-7-(4-chlorobenzylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine (13b). From 6b; yield 54% from 2-propanol;
orange crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3252; 1H-NMR (DMSO-d6) δ 9.34 (d,
1H, H-9); 8.81 (dd, 1H, H-8); 8.59 (d, 1H, H-6); 8.10 (s, 1H,
H-2); 7.49 (d, 2H, Ph); 7.43 (m, 2H, Ph); 7.18 (t, 1H, NH
exch.); 4.49 (d, 2H, CH2); 2.55 (s, 3H, CH3). Anal. Calcd C, H,
N: C, 63.06%; H, 4.36%; N, 21.63%. Found: C, 63.47%; H,
4.32%; N, 21.59%.
3-Methyl-7-(2-pyridinylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine (13c). From 6b; yield 35% from 2-propanol;
brown crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3327; 1H-NMR (DMSO-d6) δ 9.39 (d,
1H, H-9); 8.81 (dd, 1H, H-8); 8.59 (d, 1H, Py); 8.47 (m, 2H,
H-2 and H-6); 8.17 (m, 1H, Py); 7.48–7.42 (m, 2H, Py); 7.34
(t, 1H, Py); 7.25 (t, 1H, NH exch.); 4.55 (d, 2H, CH2); 2.62 (s,
3H, CH3). Anal. Calcd C, H, N: C, 66.19%; H, 4.86%; N,
28.95%. Found: C, 66.25%; H, 4.82%; N, 29.05%.
3-(1,2,4-Triazol-3-yl)-7-benzylaminopyrazolo[5,1-c][1,2,4]
benzotriazine (18a). From 17; yield 65.4% from
methoxyethanol; red crystals; TLC eluent: toluene/ethyl
acetate/acetic acid 8:2:1 v/v/v; IR ν cm1 3331, 3210; 1H-NMR
(DMSO-d6) δ 9.71 (bs, 1H, NH triazole exch.), 8.54 (s, 1H,
H-2); 8.38 (s, 1H, CH); 8.24 (d, 1H, H-9); 7.58 (dd, 1H, H-8);
7.46 (m, 3H, H-6 and Ph); 7.36 (t, 2H, Ph); 7.26 (t, 1H, Ph);
7.21 (t, 1H, NH exch.); 4.51 (d, 2H, CH2). Anal. Calcd C, H,
N: C, 63.15%; H, 4.12%; N, 32.73%. Found: C, 63.37%; H,
4.18%; N, 32.78%.
3-(1,2,4-Triazol-3-yl)-7-(4-chlorobenzylamino)pyrazolo[5,1-c]
[1,2,4]benzotriazine (18b). From 17; yield 58% from
methoxyethanol; red crystals; TLC eluent: toluene/ethyl
acetate/acetic acid 8:2:1 v/v/v; IR ν cm1 3281, 3210; 1H-NMR
(DMSO-d6) δ 10.1 (bs, 1H, NH exch.); 8.50 (s, 1H, H-2); 8.35
(s, 1H, CH); 8.24 (d, 1H, H-9); 7.60 (dd, 1H, H-8); 7.39 (m,
4H, Ph); 7.37 (d, 1H, H-6); 5.27 (t, 1H, NH exch.); 4.53 (d, 2H,
CH2). Anal. Calcd C, H, N: C, 53.38%; H, 3.48%; N, 29.74%.
Found: C, 57.45%; H, 3.43%; N, 29.71%.
3-(1,2,4-Triazol-3-yl)-7-(2-pyridinylmethylamino)pyrazolo[5,1-c]
[1,2,4]benzotriazine (18c). From 17; yield 35% from ethanol; red
crystals; TLC eluent: toluene/ethyl acetate/methanol 8:2:1 v/v/v; IR ν
cm1 3331, 3220; 1H-NMR (DMSO-d6) δ 10.1 (bs, 1H, NH exch.);
8.48 (d, 1H, Py); 8.26 (s, 1H, H-2); 8.17 (m, 2H, CH and H-9); 7.76
(m, 1H, Py); 7.54 (dd, 1H, H-8); 7.46 (m, 2H, H-6 and Py); 7.24 (m,
1H, Py); 5.38 (t, 1H, NH exch.); 4.56 (d, 2H, CH2). Anal. Calcd C,
H, N: C, 59.47%; H, 3.82%; N, 36.72%. Found: C, 59.51%; H,
3.85%; N, 36.77%.
3-(1,2,4-Triazol-3-yl)-7-(furan-2-methylamino)pyrazolo[5,1-c]
[1,2,4]benzotriazine (18d). From 17; yield 60.5% from ethanol;
light violet crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; IR ν cm1 3318, 3210; 1H-NMR (DMSO-d6) δ 9.20
(bs, 1H, NH exch.); 8.11 (m, 2H, H-2 and CH); 7.65 (d, 1H,
H-9); 7.55 (m, 1H, furane); 6.60 (d, 1H, H-8); 6.43 (m, 2H, H-8
and furane); 6.26 (m, 1H, furane); 6.89 (t, 1H, NH exch.); 4.50
(d, 2H, CH2). Anal. Calcd C, H, N: C, 57.83%; H, 3.64%; N,
33.72%. Found: C, 57.47%; H, 3.59%; N, 33.68%.
General procedure for the synthesis of 15 and 23. The
starting material, 3-carbamoyl-7-nitropyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide 14 [18] and 22 (0.182 mmol), was
solubilized in a mixture of anhydrous toluene (5 mL) and
anhydrous dimethylformamide (2 mL), then DMF-DMA
(0.3 mL) was added. The reaction was maintained at reflux
temperature and monitored by TLC until the starting material
disappeared. The final suspension was filtered, and the product,
washed with di-isopropyl ether, was pure enough and used in
the next reaction.
3-(N-(Dimethylaminomethylene)carbamoyl)-7-nitropyrazolo[5,1-c]
[1,2,4]benzotriazine 5-oxide (15). From 14 [18]; green-yellow
crystals; yield 78%; TLC eluent: toluene/ethyl acetate/methanol
8:2:2 v/v/v; IR ν cm1 1640, 1570, 1540, 1340; 1H-NMR
(DMSO-d6) δ 9.04 (d, 1H, H-6); 8.83 (dd, 1H, H-8); 8.74 (s,
1H, H-2); 8.64 (s, 1H, CH); 8.57 (d, 1H, H-9); 3.21 (s, 3H,
CH3); 3.19 (s, 3H, CH3). Anal. Calcd C, H, N: C, 47.42%; H,
3.37%; N, 29.78%. Found: C, 47.30%; H, 3.32%; N, 29.75%.
3-(N-(Dimethylaminomethylene)carbamoyl)-8-benzylaminopyrazolo
[5,1-c][1,2,4]benzo triazine 5-oxide (23). From 22; green-yellow
crystals; yield 74%; TLC eluent: toluene/ethyl acetate/methanol
8:2:2 v/v/v; IR ν cm1 3350, 1640, 1550; 1H-NMR (DMSO-d6)
δ 8.58 (s, 1H, H-5); 8.45 (s, 1H, H-2); 8.38 (t, 1H, NH exch.);
8.14 (d, 1H, H-6); 7.40 (m, 4H, Ph and H-9); 7.30 (m, 2H, Ph);
7.10 (m, 1H, H-7); 4.56 (d, 2H, CH2); 3.18 (s, 3H, CH3); 3.14
(s, 3H, CH3). Anal. Calcd C, H, N: C, 61.69%; H, 4.92%; N,
25.18%. Found: C, 61.41%; H, 4.89%; N, 25.22%.
General procedure for the synthesis of 16 and 21a. To a
suspension of 15 or 23 (0.150 mmol) in glacial acetic acid
(3 mL) was added hydrazine hydrate 55% (0.35 mmol,
0.017 mL). The reaction was kept at 90–100°C and monitored
by TLC until the starting material disappeared. The residue was
diluted with diethyl ether, filtered and recrystallized by suitable
solvent.
3-(1,2,4-Triazol-3-yl)-7-nitropyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (16). From 15; orange crystals; yield 83% from ethanol;
TLC eluent: toluene/ethyl acetate/methanol 8:2:2 v/v; IR ν cm1
3312, 1570, 1540, 1350; 1H-NMR (DMSO-d6) δ 11.7 (br, 1H, NH
exch.); 9.05 (d, 1H, H-6); 8.83 (dd, 1H, H-8); 8.78 (s, 1H, H-2);
8.58 (s, 1H, CH); 8.56 (d, 1H, H-9). Anal. Calcd C, H, N: C,
44.30%; H, 2.03%; N, 37.57%. Found: C, 44.47%; H, 2.08%; N,
37.59%.
3-(1,2,4-Triazol-3-yl)-8-benzylaminopyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (21a). From 23; orange crystals;
yield 83% from 2-propanol; TLC eluent: toluene/ethyl
acetate/methanol 8:2:1.5 v/v/v; IR ν cm1 3321, 3231, 1550;
1H–NMR (DMSO-d6) δ 14.08 (br, 1H, NH exch.); 8.51 (s,
1H, H-2); 8.37 (s, 1H, H-5); 8.15 (d, 1H, H-6); 7.40 (m, 4H,
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Ph and H-9); 7.30 (m, 2H, Ph); 7.10 (m, 2H, H-7 and NH
exch.); 4.56 (d, 2H, CH2). Anal. Calcd C, H, N: C, 60.33%;
H, 3.94%; N, 31.27%. Found: C, 60.47%; H, 3.98%; N,
31.31%.
3-(1,2,4-Triazol-3-yl)-7-aminopyrazolo[5,1-c][1,2,4]benzotriazine
(17). To a suspension of 16 (0.150 mmol) in conc. hydrochloride
acid (3 mL) at 0°C was added, in portions, tin (150 mg). After
15 min, the reaction finished (by TLC) and the inorganic precipitate,
SnCl4, was solubilized by treatment with a 10% sodium hydroxide
solution until pH 10.
The desired final product, instead, was recovered as red
precipitate, filtered and recrystallized by ethanol. Yield 72%;
TLC eluent: dichloromethane/methanol 10:0.5 v/v; IR ν cm1
3344, 3240, 3218; 1H-NMR (DMSO-d6) δ 14.2 (br, 1H, NH
exch.); 8.72 (s, 1H, H-2); 8.27 (d, 1H, H-9); 8.12 (s, 1H, CH);
7.61 (d, 1H, H-6); 7.54 (dd, 1H, H-8); 6.05 (bs, 2H, NH2
exch.); Anal. Calcd C, H, N: C, 52.38%; H, 3.20%; N, 44.42%.
Found: C, 52.45%; H, 3.25%; N, 44.39%.
General procedure for the synthesis of 21b–d and 22. A
solution of starting material 3-(1,2,4-triazol-3-yl)-8-
chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide 20 [19] or 19
[18] (0.150 mmol) in dimethylformamide (5 mL) was added of
the suitable aromatic amine (2 mL, benzylamine 4-
chlorobenzylamine, 2-aminomethylpyridine, furfurylamine) and
vrefluxed monitoring the reaction by TLC. The final solution
was cooled, and the addition of water gave a precipitate that
was recrystallized or purified by chromatography column.
3-(1,2,4-Triazol-3-yl)-8-(4-chlorobenzylamino)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (21b). From 20 [19] with 4-
chlorobenzylamine, yield 48% from chromatography column
(eluent toluene/ethyl acetate/acetic acid 8:2:1 v/v); orange
crystals; IR ν cm1 3331, 3210, 1570; 1H-NMR (DMSO-d6) δ
14.1 (bs, 1H, NH exch.); 7.91 (m, 2H, H-2 and CH); 7.56 (d,
1H, H-6); 7.39–7.32 (m, 5H, Ph and NH exch.); 6.60 (dd, 1H,
H-7); 6.43 (d, 1H, H-9); 4.46 (d, 2H, CH2). Anal. Calcd C, H,
N: C, 55.04%; H, 3.34%; N, 28.53%. Found: C, 55.31%; H,
3.37%; N, 28.50%.
3-(1,2,4-Triazol-3-yl)-8-(4-pyridinilmethylamino)pyrazolo[5,1-c]
[1,2,4]benzotriazine 5-oxide (21c). From 20 [19] with 2-
aminomethylpyridine; yield 55% from water; TLC eluent:
toluene/ethyl acetate/acetic acid 8:2:1 v/v; orange crystals; IR ν
cm1 3319, 3213, 1570; 1H-NMR (DMSO-d6) δ 9.74 (bs, 1H, NH
exch.); 8.63 (m, 2H, Py); 8.54 (s, 1H, H-2); 8.52 (s, 1H, CH); 8.06
(d, 1H, H-6); 7.83 (d, 1H, H-9); 7.53 (m, 2H, Py); 7.43 (dd, 1H,
H-7); 7.21 (t, 1H, NH exch.); 4.52 (d, 2H, CH2). Anal. Calcd C, H,
N: C, 56.82%; H, 3.65%; N, 35.08%. Found: C, 56.59%; H,
3.62%; N, 35.18%.
3-(1,2,4-Triazol-3-yl)-8-(furan-2-methylamino)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (21d). From 20 [19] with
furfurylamine; yield 48.3% from water; brown crystals; TLC
eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v; IR ν cm1
3331, 3220, 1550; 1H-NMR (DMSO-d6) δ 9.20 (bs, 1H, NH
exch.); 7.90 (s, 1H, CH); 7.58 (m, 2H, H-6 and H-2); 7.55 (m,
1H, furane); 7.18 (d, 1H, H-9); 7.03 (dd, 1H, H-7); 6.43 (m,
2H, furane); 6.89 (t, 1H, NH exch.); 4.55 (d, 2H, CH2). Anal.
Calcd C, H, N: C, 55.17%; H, 3.47%; N, 32.17%. Found: C,
55.31%; H, 3.43%; N, 32.15%.
3-Carbamoyl-8-benzylaminopyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (22). From 19 [18] with benzylamine, orange crystals;
yield 86%; TLC eluent: toluene/ethyl acetate/ 8:2 v/v; IR ν cm1
3335, 3211 1640, 1550; 1H-NMR (DMSO-d6) δ 8.43 (t, 1H, NH
exch.); 8.41 (s, 1H, H-2); 8.15 (d, 1H, H-6); 7.45 (bs, 1H, NH
exch.); 7.40 (m, 4H, Ph, and H-9); 7.30 (m, 2H, Ph); 7.10 (m,
1H, H-7); 6.98 (bs, 1H, NH exch.); 4.56 (d, 1H, CH2). Anal.
Calcd C, H, N: C, 61.07%; H, 4.22%; N, 25.14%. Found: C,
61.32%; H, 4.25%; N, 25.20%.
Biological. Radioligand binding assay. [3H]Ro 15-1788
(specific activity 78.8 Ci/mmol) was obtained from Perkin
Elmer. All the other chemicals, which were of reagent grade,
were obtained from commercial suppliers. Bovine cerebral
cortex membranes were prepared as previously described
[33,34]. The membrane preparations were diluted with
50 mM tris-citrate buffer pH 7.4, and used in the binding
assay. Protein concentration was assayed using the method of
Lowry et al. [35]; [3H]Ro 15-1788 binding studies were
performed as previously reported [19]. At least six different
concentrations of each compound were used. The data of
n = 5 experiments carried out in triplicate were analyzed by
means of an iterative curve-fitting procedure (program Prism,
GraphPad, San Diego, CA), which provided IC50, Ki, and
SEM values for tested compounds, the Ki values being
calculated from the Cheng and Prusoff equation [36].
Pharmacological methods.
Animals. Male Swiss albino mice (23–30 g) and male
Sprague Dowley rats from the Harlan-(Varese) breeding
farm were used. Fifteen mice or four rats were housed per
cage. The cages were placed in the experimental room 24 h
before the test for acclimatization. The animals were kept at
23 ± 1°C with a 12 h light/dark cycle, light at 7 AM, with
food and water ad libitum. All experiments were carried out
according to the guidelines of the European Community
Council.
Pentylenetetrazole-induced seizure. Pentylentetrazole
(90 mg/kg s.c.) was injected 30 min after the administration of
drugs. The frequency of the occurrence of clonic generalized
convulsions was noted over a period of 30 min.
Mouse light/dark box test. The apparatus (50 cm long,
20 cm wide, and 20 cm high) consisted of two equal acrylic
compartments, one dark and one light, illuminated by a 60 W
bulb lamp and separated by a divider with a 10 × 3-cm
opening at floor level. Each mouse was tested by placing it
in the center of the lighted area, facing away from the dark
one, and allowing it to explore the novel environment for
5 min. The number of transfers from one compartment to the
other and the time spent in the illuminated side were
measured. This test exploited the conflict between the
animal’s tendency to explore a new environment and its fear
of bright light.
Hot plate test. The method adopted was described by
O’Callaghan and Holzman [37]. Mice were placed inside a
stainless steel container, thermostatically set at 52.5 ± 0.1°C in
a precision water-bath from KW Mechanical Workshop, Siena,
Italy. Reaction times (s), were measured with a stop-watch before
i.c.v. injections and at regular intervals (15 min) up to a maximum
of 60 min after treatment (cut-off) in order to prevent tissue dam-
age. The endpoint used was the licking of the fore or hind paws.
Antinociception was seen as increased latencies to the responses
evaluated, while increased nociception was seen by shorter laten-
cies. Those mice scoring below 12 and over 18 s in the pretest
were rejected (30%). An arbitrary cut-off time of 45 s was
adopted.
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Abdominal constriction test. Mice were injected i.p. with a
0.6% solution of acetic acid (10 mL/kg), according to Koster [38].
The number of stretching movements was counted for 10 min,
starting 5 min after acetic acid injection.
Paw pressure test. The nociceptive threshold in the rat
was determined with an analgesimeter (Ugo Basile, Varese,
Italy), according to the method described by Leighton [22].
The instrument exerts a force that is applied at a costant rate
(32 g per second) with a cone-shaped pusher on the upper sur-
face of the rat hind paw. The force is continuously monitored
by a pointer moving along a linear scale. The pain threshold
is given by the force that induces the first struggling from the
rat. Pretested rats that scored below 40 g or over 75 g during
the test before drug administration (25%) were rejected. An
arbitrary cut off value of 250 g was adopted.
Chronic constriction injury. A peripheral mononeuropathy
was produced in adult rats by placing loosely constrictive
ligatures around the common sciatic nerve according to the
method described by Bennett [21]. Rats were anesthetized
with chloral hydrate. The common sciatic nerve was exposed
at the level of the middle of the thigh by blunt dissection
through biceps femoris. Proximal to sciatica’s tri furcation,
about 1 cm of the nerve was freed of adhering tissue and four
ligatures (3/0 silk tread) were tied loosely around it with
about 1 mm spacing. The length of the nerve thus affected
was 4–5 mm long. Great care was taken to tie the ligatures
such that the diameter of the nerve was seen to be just barely
constricted when viewed with 40× magnification. In every
animal, an identical dissection was performed on the opposite
side except that the sciatic nerve was not ligated. The left paw
was untouched.
Induction of diabetes (streptozotocin treatment).
Streptozotocin (200 mg kg1) was solubilized in a saline
solution (pH 4.5 in 0.1 N sodium citrate buffer). Mice were
divided in two groups that received in the tail vein STZ or
vehicle, respectively. STZ increases serum glucose level (above
300 mg/dl; measured by the glucose oxidase method) 7, 14, and
21 days after injection treatment. A significant thermal
hyperalgesia is well established on day 21 [39]. Behavioral tests
were performed on day 21, after a preliminary evaluation of the
pain threshold (mice scoring over 20 s in the hot plate test were
rejected). Measurements were performed over time (30, 60, 90,
and 120 min) after the administration of test compound.
Drugs. Diazepam (Valium 10 – Roche), flumazenil (Roche),
PTZ (Sigma), and zolpidem (Tocris) were used. All drugs except
PTZ were suspended in 1% carboxymethylcellulose sodium salt
and sonicated immediately before use. PTZ was dissolved in an
isotonic (NaCl 0.9%) saline solution and injected s.c. All
benzodiazepine receptor ligands were administered by p.o.
route, except for flumazenil, which was administered i.p. Drug
concentrations were prepared in such a way that the necessary
dose could be administered in a volume of 10 mL/kg by the
p.o., i.p., or s.c. routes.
Statistical analysis. All experimental results are given as the
mean ± S.E.M. Analysis of variance, followed by Fisher’s
Protected Least Significant Difference procedure for post hoc
comparison, was used to verify significance between two
means. Data were analyzed with the StatView software for the
Macintosh (1992). P values of less than 0.05 were considered
significant.
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